Core Viewpoint - China Tongru (01763) experienced a significant stock increase of over 10% following the launch of its carbon isotope product and the second phase of its stable isotope base project in Tongcheng, Anhui, which is expected to enhance domestic production capabilities in the medical isotope sector [1] Group 1: Company Developments - The launch event on October 31 marked the initiation of a project that will produce 2,000 kilograms of high-abundance 13CO gas and 4,000 kilograms of 13C urea raw materials annually [1] - The high-abundance 13CO gas is a critical raw material used in urea breath tests for detecting Helicobacter pylori infections [1] - The project signifies a shift from reliance on imported 13CO gas for urea breath diagnostic materials, establishing a fully autonomous supply chain in the medical stable isotope carbon field in China [1] Group 2: Industry Impact - The establishment of this production line is expected to provide a solid foundation for creating a safe and reliable high-end medical isotope supply chain in China [1] - The project represents a comprehensive control over the entire industry chain from key raw materials to end products in the medical stable isotope sector [1]

Core Viewpoint - The launch of the stable isotope base phase II project by China Tongfu marks a significant advancement in the domestic production of high-abundance 13CO gas and 13C urea raw materials, reducing reliance on imports and establishing a comprehensive domestic supply chain for medical stable isotopes [1] Group 1 - The project, initiated on October 31, aims to produce 2000 kilograms of high-abundance 13CO gas and 4000 kilograms of 13C urea raw materials annually [1] - High-abundance 13CO gas is a critical raw material used in the urea breath test for detecting Helicobacter pylori infections [1] - The launch signifies China's achievement in establishing a fully autonomous and controllable supply chain in the medical stable isotope carbon sector, from key raw materials to end products [1]

Core Viewpoint - China Tongru (01763) has made a significant breakthrough in the field of stable isotopes by launching carbon isotope products, marking China's advancement in high-end technology and reducing reliance on imports for key medical materials [1] Group 1: Product Launch and Significance - The launch of high-abundance 13CO gas and carbon-13 urea raw materials positions China as one of the few countries capable of producing these essential components for medical applications [1] - The new products will eliminate China's complete dependence on imports for 13CO used in urea breath tests for detecting Helicobacter pylori infections, enhancing domestic production capabilities [1] Group 2: Industry Impact and Future Projects - The announcement coincides with the initiation of the second phase of the stable isotope base project, which will ensure a stable supply of high-abundance 13CO gas and other raw materials for gastrointestinal disease treatments [1] - This development is expected to significantly contribute to national health improvement and the high-quality development of medical isotopes, aligning with the "Healthy China" initiative [1]

Core Viewpoint - China Tongru (01763.HK) has announced the launch of carbon isotope products, marking a significant breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials for pharmaceuticals [1] Group 1: Product Launch and Significance - The release of high-abundance 13CO gas is crucial for the urea breath test used to detect Helicobacter pylori infection, indicating a shift from complete reliance on imports for this material [1] - This product launch significantly enhances China's research and production capabilities in stable isotope products, positioning China Tongru as a leading enterprise with a complete grasp of the entire industrial chain for breath test products [1] Group 2: Future Developments - On the same day, China Tongru officially commenced the construction of the second phase of its stable isotope base project, which will establish a stable supply capability for high-abundance 13CO gas, carbon-13 urea raw materials, and other raw materials for gastrointestinal disease treatment drugs [1] - The completion of this project is expected to contribute to improving national health levels, promoting high-quality development of medical isotopes, and supporting the "Healthy China" initiative [1]